Back to top

Analyst Blog

On Apr 17, we downgraded our recommendation on Myriad Genetics Inc. (MYGN - Analyst Report) to Neutral from Outperform. Despite the recent healthy growth, the stock is presently out of favor on account of imminent headwinds.

Why Downgraded?

Presently, there is a lot of uncertainty surrounding Myriad. While the company started fiscal 2013 on a solid note, several downsides such as reimbursement issues and ongoing patent litigation weigh on the stock.

The Noridian reimbursement price cut for the integrated Bracanalysis test is a major cause of concern. We are wary that if private insurance payors follow suit, the reimbursement cut might adversely impact Myriad.

Further, Myriad continues to face legal claims that challenge its patent landscape. The ongoing patent litigation (to decide whether isolated human genes can be patented) might drag the stock. We are concerned that an adverse outcome might affect the patent landscape for the company’s flagship product, which in turn might impact the Myriad’s growth over the long haul.

We also keep an eye on the product development timelines. With several tests under early-stage development, Myriad continues to face higher costs. Consequently, gross margin pressure is another cause of concern. Also, uncertainties in Europe remain an overhang.

Although Myriad still expects fiscal revenues and EPS to come in at the high end of the guidance, the issue surrounding the stock leads to a somewhat pessimistic view that the company might not be able to keep the recent momentum going over the long haul.

We await Myriad’s recovery from the ongoing challenges. Myriad presently carries a Zacks Rank #4 (Sell). However, other medical sector stocks such as Cyberonics Inc. (CYBX - Analyst Report) and Cepheid (CPHD - Analyst Report), carrying a Zacks Rank #1 (Strong Buy) are expected to do well. Abiomed Inc. (ABMD - Analyst Report), carrying a Zacks Rank #2 (Buy) is also worth considering.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%